Universe Pharmaceuticals (UPC) Receivables (2020 - 2025)

Universe Pharmaceuticals has disclosed Receivables across 6 years of filings, most recently posting $15.3 billion for Q3 2025.

• Receivables for Q3 2025 came in at $15.3 billion, down 17.68% year-over-year; the trailing twelve-month figure through Sep 2025 was $15.3 billion (down 17.68% YoY), and the FY2025 annual result was $15.3 billion, down 17.68% from the prior year.
• Receivables came in at $15.3 billion for Q3 2025 at Universe Pharmaceuticals, down from $18.6 billion in the prior quarter.
• In the past five years, Receivables ranged from a high of $18.6 billion in Q3 2024 to a low of $12.9 million in Q3 2023.
• The 5-year median for Receivables is $16.9 million (2021), against an average of $4.2 billion.
• Across the five-year window, Receivables tumbled 100.0% in 2021 and surged 143480.89% in 2024, its largest moves.
• Universe Pharmaceuticals' Receivables stood at $16.3 million in 2021, then fell by 6.6% to $15.2 million in 2022, then retreated by 14.81% to $12.9 million in 2023, then soared by 143480.89% to $18.6 billion in 2024, then declined by 17.68% to $15.3 billion in 2025.
• The last three Receivables figures came in at $15.3 billion (Q3 2025), $18.6 billion (Q3 2024), and $14.4 million (Q1 2024), per Business Quant data.